Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease
Sponsor: Keymed Biosciences Co.Ltd
Summary
This is a randomized, double-blind, placebo-controlled and multiple dose escalation phase Ib study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM383 in patients with Alzheimer's disease related mild cognitive impairment and mild Alzheimer's disease.
Official title: A Randomized, Double-blind, Placebo-controlled and Multiple Dose Escalation Phase Ib Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease
Key Details
Gender
All
Age Range
50 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2024-11-08
Completion Date
2026-12-30
Last Updated
2025-03-19
Healthy Volunteers
No
Conditions
Interventions
Alzheimer Disease (AD)
CM383 injection
Placebo
Matched placebo
Locations (1)
The First Affiliated Hospital of University of Science and Technology of China
Hefei, China